A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.

Nat Commun · 2026 · PMC13287472 · PMID 42014686

Europe PMC DOI

hedged sentence

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not reach statistical significancep = 0.19not close (p > 0.1)

Although an upward trend was observed relative to dorzagliatin monotherapy, this difference did not reach statistical significance (p = 0.19, |Cohen’s d | =0.714) (Fig. 1b ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.